Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published 6 March 2009
Cite this as: BMJ Case Reports 2009 [doi:10.1136/bcr.09.2008.0845]
Copyright © 2009 by the BMJ Publishing Group Ltd.

Unexpected outcome (positive or negative) including adverse drug reactions

New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis

Christina Jost1, Josef Hermann1, Laila El-Shabrawi Caelen2, Winfried Graninger1

1 Medical University Hospital Graz, Division of Rheumatology, Auenbruggerplatz 15, Graz, 8036, Austria
2 University Hospital Graz, Department for Dermatology and Venerology, Auenbruggerplatz 8, Graz, 8036, Austria

Correspondence to:
Christina Jost, christina.jost{at}klinikum-graz.at

SUMMARY

Administration of abatacept is a new treatment modality for rheumatoid arthritis (RA). We describe a patient in whom psoriasiform skin lesions developed 4 months after the initiation of abatacept therapy for longstanding, rheumatoid factor positive RA. Histological findings were consistent with psoriasis. The skin lesions subsided after discontinuation of abatacept and reappeared after re-exposure to the drug, suggesting a causal connection between abatacept and the development of psoriasis.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) -   become a fellow  today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts  so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog